{"id":"W4389893007","doi":"10.1016/j.msard.2023.105328","title":"Design and Baseline Characteristics of Phase 3, Double-Blind, Randomised Trials Evaluating the Efficacy and Safety of Evobrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis (evolutionRMS 1 and 2)","year":2023,"lang":"en","type":"article","venue":"Multiple Sclerosis and Related Disorders","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"NeuroRx Research (Canada); Montreal Neurological Institute and Hospital","funders":"","keywords":"Teriflunomide; Medicine; Multiple sclerosis; Internal medicine; Relapsing remitting; Clinical trial; Physical therapy; Oncology; Immunology; Fingolimod","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007066653,0.000295309,0.001061707,0.0003292673,0.0002394567,0.00004616565,0.00009529606,0.0002649551,0.00001995021],"category_scores_gemma":[0.00770906,0.0002106126,0.0001064141,0.0006704924,0.0007288088,0.0001242922,0.0001753203,0.0003482492,0.000001351609],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003612574,"about_ca_system_score_gemma":0.0005965027,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006331498,"about_ca_topic_score_gemma":0.00004155494,"domain_scores_codex":[0.9963925,0.0007898926,0.001434696,0.0005312437,0.0004205671,0.000431109],"domain_scores_gemma":[0.9897241,0.009135425,0.0004859865,0.000330189,0.0001390681,0.000185212],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5955535,0.0007802488,0.00608129,0.0006072588,0.0006855096,0.0000063737,0.005929193,0.001415465,0.1895266,0.00001608543,0.00008906596,0.1993095],"study_design_scores_gemma":[0.614617,0.0008820172,0.02771502,0.001073413,0.000386362,0.000006685449,0.0007270349,0.3533922,0.0009789187,0.00001468013,0.00002047003,0.0001862772],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922429,0.003387266,0.0003289481,0.0004643256,0.0001813235,0.003278808,0.00004450286,0.00004292581,0.00002894647],"genre_scores_gemma":[0.982022,0.01692564,0.000740028,0.00001349791,0.00002819358,0.00009213322,0.00008181582,0.0000438492,0.00005280174],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3519767,"threshold_uncertainty_score":0.9229022,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1882112032418722,"score_gpt":0.3692451553097669,"score_spread":0.1810339520678947,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}